Raymond James & Associates Sells 478 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Raymond James & Associates decreased its stake in BeiGene, Ltd. (NASDAQ:BGNE) by 3.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,597 shares of the company’s stock after selling 478 shares during the period. Raymond James & Associates’ holdings in BeiGene were worth $2,272,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BGNE. E Fund Management Hong Kong Co. Ltd. lifted its stake in BeiGene by 137.7% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 27,501 shares of the company’s stock valued at $5,071,000 after purchasing an additional 15,929 shares during the last quarter. Bank of New York Mellon Corp increased its position in BeiGene by 0.6% in the 1st quarter. Bank of New York Mellon Corp now owns 55,199 shares of the company’s stock valued at $10,409,000 after acquiring an additional 308 shares during the period. American Century Companies Inc. increased its position in BeiGene by 7.9% in the 1st quarter. American Century Companies Inc. now owns 3,458 shares of the company’s stock valued at $652,000 after acquiring an additional 254 shares during the period. Bank of Montreal Can increased its position in BeiGene by 19.7% in the 1st quarter. Bank of Montreal Can now owns 14,571 shares of the company’s stock valued at $3,001,000 after acquiring an additional 2,396 shares during the period. Finally, Panagora Asset Management Inc. increased its position in BeiGene by 3.7% in the 1st quarter. Panagora Asset Management Inc. now owns 5,195 shares of the company’s stock valued at $980,000 after acquiring an additional 183 shares during the period. Institutional investors own 48.55% of the company’s stock.

Insiders Place Their Bets

In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other BeiGene news, CFO Julia Aijun Wang sold 397 shares of the firm’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO John Oyler sold 37,668 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $164.02, for a total transaction of $6,178,305.36. Following the completion of the transaction, the chief executive officer now directly owns 12,332 shares in the company, valued at $2,022,694.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,781 shares of company stock worth $10,222,381. 7.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BGNE shares. Bank of America decreased their price target on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating for the company in a research report on Monday, April 8th. Guggenheim decreased their price target on shares of BeiGene from $350.00 to $345.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Sanford C. Bernstein decreased their price objective on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. increased their price objective on shares of BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $251.70.

BeiGene Trading Down 3.1 %

NASDAQ:BGNE opened at $134.05 on Wednesday. The company has a current ratio of 2.32, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $12.82 billion, a price-to-earnings ratio of -15.77 and a beta of 0.61. The firm has a fifty day simple moving average of $156.36 and a two-hundred day simple moving average of $169.45. BeiGene, Ltd. has a 12 month low of $132.95 and a 12 month high of $270.57.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings results on Monday, February 26th. The company reported ($3.53) EPS for the quarter, topping analysts’ consensus estimates of ($3.61) by $0.08. The business had revenue of $634.40 million during the quarter, compared to analysts’ expectations of $632.52 million. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The business’s quarterly revenue was up 66.9% on a year-over-year basis. During the same period last year, the company posted ($4.29) earnings per share. Analysts expect that BeiGene, Ltd. will post -8.87 EPS for the current fiscal year.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.